NCT06771674 2025-09-09Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell CarcinomaHookipa Biotech GmbHCompleted662 enrolled
NCT07015333 2025-06-11Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and CetuximabCommonwealth Healthcare CorporationCompleted31 enrolled
NCT04740996 2022-02-07Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in ChinaChineseAMSUnknown30 enrolled